Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study.
van Loevezijn AA, van der Noordaa MEM, van Werkhoven ED, Loo CE, Winter-Warnars GAO, Wiersma T, van de Vijver KK, Groen EJ, Blanken-Peeters CFJM, Zonneveld BJGL, Sonke GS, van Duijnhoven FH, Vrancken Peeters MTFD. van Loevezijn AA, et al. Among authors: wiersma t. Ann Surg Oncol. 2021 Jun;28(6):3243-3253. doi: 10.1245/s10434-020-09273-0. Epub 2020 Dec 2. Ann Surg Oncol. 2021. PMID: 33263830 Free PMC article.
Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment).
van der Noordaa MEM, van Duijnhoven FH, Loo CE, van Werkhoven E, van de Vijver KK, Wiersma T, Winter-Warnars HAO, Sonke GS, Vrancken Peeters MTFD. van der Noordaa MEM, et al. Among authors: wiersma t. Breast. 2018 Aug;40:76-81. doi: 10.1016/j.breast.2018.04.015. Epub 2018 May 22. Breast. 2018. PMID: 29698928
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M. Voorwerk L, et al. Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13. Nat Med. 2019. PMID: 31086347 Clinical Trial.
Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M. Voorwerk L, et al. Nat Med. 2019 Jul;25(7):1175. doi: 10.1038/s41591-019-0520-5. Nat Med. 2019. PMID: 31209337
[No title available]
[No authors listed] [No authors listed] PMID: 33031572
Erratum to "Prognostic factors in patients with oligometastatic breast cancer - A systematic review". [Cancer treatment Rev. 91 (2020) 102114].
van Ommen-Nijhof A, Steenbruggen TG, Schats W, Wiersma T, Horlings HM, Mann R, Koppert L, van Werkhoven E, Sonke GS, Jager A. van Ommen-Nijhof A, et al. Among authors: wiersma t. Cancer Treat Rev. 2021 Jan;92:102138. doi: 10.1016/j.ctrv.2020.102138. Epub 2020 Dec 17. Cancer Treat Rev. 2021. PMID: 33342599 No abstract available.
Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
Steenbruggen TG, Schaapveld M, Horlings HM, Sanders J, Hogewoning SJ, Lips EH, Vrancken Peeters MT, Kok NF, Wiersma T, Esserman L, van 't Veer LJ, Linn SC, Siesling S, Sonke GS. Steenbruggen TG, et al. Among authors: wiersma t. JNCI Cancer Spectr. 2021 Feb 4;5(3):pkab010. doi: 10.1093/jncics/pkab010. eCollection 2021 Jun. JNCI Cancer Spectr. 2021. PMID: 33977227 Free PMC article.
Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience.
van der Noordaa MEM, Ioan I, Rutgers EJ, van Werkhoven E, Loo CE, Voorthuis R, Wesseling J, van Urk J, Wiersma T, Dezentje V, Vrancken Peeters MTFD, van Duijnhoven FH. van der Noordaa MEM, et al. Among authors: wiersma t. Ann Surg Oncol. 2021 Nov;28(12):7383-7394. doi: 10.1245/s10434-021-09865-4. Epub 2021 May 12. Ann Surg Oncol. 2021. PMID: 33978889
Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer.
van der Noordaa MEM, van Duijnhoven FH, Cuijpers FNE, van Werkhoven E, Wiersma TG, Elkhuizen PHM, Winter-Warnars G, Dezentje V, Sonke GS, Groen EJ, Stokkel M, Vrancken Peeters MTFD. van der Noordaa MEM, et al. Among authors: wiersma tg. Br J Surg. 2021 Jun 22;108(6):667-674. doi: 10.1002/bjs.12026. Br J Surg. 2021. PMID: 34157085
129 results